Epidarex Capital has launched a new drug discovery initiative providing seed funding and hands-on support to nurture fledgling projects.
Epidarex Capital, a UK-based specialist life sciences VC firm whose focus includes spinouts, unveiled a new drug discovery program yesterday aimed at sustaining early-stage projects until they become investable assets.
Epidarex Exeed will mature portfolio projects over 12 to 18 months with resources including seed funding from Epidarex as they prepare their proposals to secure series A capital from traditional venture capital investors.
In addition to funding, Exeed will lend active assistance to derisk its selected concepts, working…
